MedImmune Plans To Expand Sales Force As It Reacquires Synagis Promotion Rights
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott will release co-promotion rights for the respiratory syncytial virus therapy effective June 30, 2006.
You may also be interested in...
MedImmune To Release Phase III Data By Year-End For Synagis Follow-On
MedImmune is on track to launch the newest member of its respiratory syncytial virus therapy franchise for the 2008–2009 respiratory virus season.
MedImmune To Release Phase III Data By Year-End For Synagis Follow-On
MedImmune is on track to launch the newest member of its respiratory syncytial virus therapy franchise for the 2008–2009 respiratory virus season.
Supreme Court To Hear MedImmune Patent Case Against Genentech
MedImmune’s suit challenges the validity of the Cabilly patent, which it licenses from Genentech.